Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis.
Publication/Presentation Date
10-1-2023
Abstract
BACKGROUND AND OBJECTIVES: The incidence of morbidity and mortality in patients with type 2 diabetes mellitus is substantially correlated with cardiovascular disease and chronic kidney disease. The current guidelines recommend the use of renin-angiotensin system blockers, but recent studies probed into the effects of finerenone to mitigate the risk of cardiorenal events. This meta-analysis was performed to demonstrate the effects of finerenone on cardiorenal events, comprising cardiovascular mortality, heart failure, change in estimated glomerular filtration rate, and serum potassium levels.
METHODS: After screening with our eligibility criteria, 350 articles were identified with an initial literature search on multiple databases, including PubMed, Science Direct, and Cochrane Central. Seven randomized controlled trials with a total of 15 462 patients (
RESULTS: Patients receiving finerenone were at a reduced risk for cardiovascular mortality [HR: 0.84 (0.74, 0.95)], heart failure [OR: 0.79 (0.68, 0.92)], decrease in estimated glomerular filtration rate by 40% [OR: 0.82 (0.74, 0.91)] and by 57% [OR: 0.70 (0.59, 0.82)]; and a higher incidence of moderate hyperkalemia [OR: 2.25 (1.78, 2.84)].
CONCLUSION: Finerenone, owing to its better mineralocorticoid affinity, and a much lower risk of adverse effects, promises to be a much better alternative than other renin-angiotensin system blockers available for the treatment of chronic kidney disease patients with type 2 diabetes. Further trials should be conducted to provide more definitive evidence to assess the safety and efficacy of finerenone compared to spironolactone and eplerenone.
Volume
85
Issue
10
First Page
4973
Last Page
4980
ISSN
2049-0801
Published In/Presented At
Yasmin, F., Aamir, M., Najeeb, H., Atif, A. R., Siddiqui, A. H., Ahsan, M. N., Moeed, A., Ali, S. H., Tahir, H. M., & Asghar, M. S. (2023). Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis. Annals of medicine and surgery (2012), 85(10), 4973–4980. https://doi.org/10.1097/MS9.0000000000001180
Disciplines
Medicine and Health Sciences
PubMedID
37811017
Department(s)
Department of Surgery, Department of Surgery Residents, Fellows and Residents
Document Type
Article